Buprenorphine Formulations: Tablets, Films and Long-Acting Injections

Buprenorphine for opioid use disorder is available in several formulations, including medicines absorbed in the mouth and long-acting injections in some countries. The choice affects administration, appointments, storage, and how treatment starts. Buprenorphine products used for pain should not be assumed equivalent to products approved for opioid use disorder.

The treatment indication comes first

A label may describe a tablet, film, patch, or injection, but the route alone does not tell you whether it treats opioid use disorder. Some buprenorphine products are intended for pain and use different exposure patterns. A prescriber should identify the exact indication and product before discussing a switch.

For opioid use disorder, treatment aims to control withdrawal and cravings and reduce harmful opioid use. A useful formulation is one the person can start safely and continue consistently. Convenience, privacy, appointment access, and preferences all matter alongside the medicine's pharmacology.

Tablets and films absorbed in the mouth

Sublingual or buccal medicines must be taken according to the exact product instructions. Swallowing immediately, moving the medicine incorrectly, or substituting another product can affect delivery. Some contain buprenorphine alone; others combine it with naloxone. The combination does not function as a take-home overdose-rescue dose.

Daily administration can offer flexibility but requires secure storage and a reliable routine. Oral health deserves attention with medicines dissolved in the mouth. Follow product advice and discuss dental symptoms with a dentist and the prescribing team rather than stopping useful treatment abruptly.

Long-acting injections

Long-acting injectable buprenorphine is administered by a healthcare professional, with product-dependent intervals and starting requirements. Examples include Sublocade and Brixadi in the United States, while names and availability differ elsewhere. An injection can reduce the burden of daily administration but does not remove the need for follow-up.

The formulation remains in the body after administration, so changing its effects is not immediate. Prior tolerability, eligibility, and the product's initiation instructions matter. Some injections are supplied through specific safety programs and must never be injected into a vein or administered at home.

Compare practical fit with the treating team

Switching requires exact product information

Equal printed strengths across formulations do not imply an equivalent regimen. A clinician should confirm the product, previous treatment, last dose, and planned transition. This is especially important after a gap, recent fentanyl or other opioid use, or a move between services.

Buprenorphine can cause precipitated withdrawal when initiation displaces another opioid too early. Different starting approaches exist, but they require clinical assessment and clear support. Do not create a personal schedule from a comparison table or use someone else's experience as a reliable timing rule.

Safety and treatment goals remain the same

Alcohol, benzodiazepines, and other sedatives can increase risk with any buprenorphine formulation. Tell the team about all substances and medicines so the combination can be managed. Keep naloxone available and discuss overdose prevention even when symptoms are well controlled.

Reviews should cover cravings, additional opioid use, functioning, adverse effects, and the person's treatment experience. Long-acting treatment is not automatically superior, and daily treatment is not a sign of lesser progress. The best choice supports a sustainable, respectful care plan.

Pain products and opioid-use-disorder products have different roles

Buprenorphine appears in products intended for different conditions, including pain and opioid-use disorder. A patch or another pain formulation is not automatically an equivalent substitute for an addiction-treatment product. Strength units, delivery and exposure differ. Identify the indication before comparing forms and ask the pharmacist to verify the exact product.

The buprenorphine guide explains the medicine more broadly. Do not try to convert a regimen using an online calculation or whatever product is available locally. A prescribing decision should consider the person's current treatment, tolerance, symptoms and the proposed formulation's requirements. If pain and opioid-use disorder coexist, the teams should coordinate both goals. A product selected to manage one should not inadvertently interrupt care for the other. Keeping brand, route and purpose on the medication record is especially useful during travel, emergency care and a transfer between services.

Mouth-absorbed products: technique, combinations and dental care

Sublingual and buccal products are intended to be absorbed in the mouth according to their instructions. Swallowing them like an ordinary tablet or changing the method can alter treatment. Ask the pharmacist to demonstrate correct use and explain product-specific advice. Combination products containing naloxone have a defined role and should not be interpreted as equivalent to a separate rescue naloxone treatment.

Tell the team about mouth or dental problems, and follow recommended dental care and product instructions. If technique, taste, daily remembering or privacy makes treatment difficult, discuss that rather than taking irregular amounts. A formulation review may help, but switching needs a coordinated plan. The naloxone guide explains overdose rescue as a separate issue. Do not share films or tablets or use a combination label as proof that misuse is impossible. Each product still requires appropriate storage, prescribed use and ongoing assessment of benefit and safety.

Long-acting injections: convenience and clinical commitments

A long-acting injection can reduce daily handling and support more consistent delivery, while appointment access and product-specific initiation remain important. Different injections have different schedules and eligibility requirements. A clinician should explain the exact product, how it is started and what happens if an appointment is late. Do not infer the plan from another brand's interval.

Discuss whether the formulation fits work, travel, privacy and personal preferences. A longer-lasting product can also make some adverse effects or changes slower to assess. Tell the service about symptoms and other substance use rather than wait for the next injection. The opioid treatment overview places formulation choice in wider care. Reliable supply and a named contact are part of the decision. An injection is not simply a way to avoid every review, nor should it be imposed as the only acceptable route when another feasible treatment would better fit the person's circumstances.

Switching formulations without losing treatment continuity

A planned switch should identify the last instructions for the old product, the start of the new one and any required assessment. The team should review recent opioid exposure, actual adherence, symptoms and interactions. An apparent formulation preference may conceal a supply problem or adverse effect that needs attention before choosing a replacement.

Ask how benefit and safety will be assessed during the change and what to do if the new product is delayed or unsuitable. Do not bridge with another person's treatment or take extra doses from the old supply. Naloxone access and overdose-prevention planning remain relevant whichever formulation is used. The regimen should support stable functioning and engagement, not only reduce daily tablet count. A clear written transition, pharmacy communication and follow-up appointment help prevent duplication or gaps. If the plan becomes impractical, contact the team early so continuity can be protected while another appropriate option is considered.

Making the next medication discussion useful

Bring one current list of medicines to the appointment, including the exact product, prescribed instructions, over-the-counter remedies, supplements and any medicines you take only occasionally. If the list in a clinic record is different from what you actually use, say so. Understanding the difference is more useful than trying to give an answer that sounds correct. A photograph of packaging can help clarify an unfamiliar brand or formulation.

Choose two or three priorities before the visit. These might be a persistent symptom, a side effect affecting daily life, a monitoring result or concern about continuing treatment. Describe when the problem began and whether it followed a change in medicine, illness, sleep or substance use. You do not have to diagnose the cause yourself. A clear timeline helps the clinician consider several explanations without automatically attributing everything to the psychiatric condition.

Leave with an agreed next step and a review date. If the plan changes, ask for written instructions that explain what each medicine is intended to do and whom to contact if a problem occurs. Check that the pharmacy and other prescribers have the updated plan. A useful review ends with responsibilities assigned, not simply with a recommendation to monitor the situation. Shared decisions should include your preferences, the available evidence and the practical ability to carry out the plan.

Related Medication and Treatment Guides

• Buprenorphine: treatment benefits, formulations and safety
• Naloxone: opioid overdose response, nasal sprays and safety
• Private Opioid Addiction Treatment & Rehab
• Explore the Medication Guide